<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01648127</url>
  </required_header>
  <id_info>
    <org_study_id>TEF-MD-01</org_study_id>
    <nct_id>NCT01648127</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Ceftaroline in Normal and Obese Subjects</brief_title>
  <official_title>Pharmacokinetics of Ceftaroline in Normal and Obese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Keith A. Rodvold</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Forest Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Illinois at Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to characterize plasma and urinary concentrations of ceftaroline
      following intravenous administration of a single dose of ceftaroline 600 mg in healthy
      subjects who are normal weight, overweight, and obese.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is planned to be a Phase I, open-label, single period, single-dose pharmacokinetic
      study conducted in 32 healthy adult male and female subjects. Adult subjects will be
      recruited and assigned to one of four groups based on their body mass index and total body
      weight. Subject will receive a single dose of ceftaroline fosamil 600 mg as a 1-hour
      continuous intravenous infusion. Serial blood and urine samples will be collected over the
      next 12 hours to determine serum and urinary pharmacokinetics of ceftaroline. Safety
      evaluations will be assessed throughout the study and will include physical examination,
      vital sign monitoring, clinical laboratory tests (serum chemistry and hematology), pregnancy
      testing (female subjects only), monitoring of adverse events, and recording of concomitant
      medications.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics of ceftaroline following intravenous administration of a single 600 mg dose to healthy subjects</measure>
    <time_frame>12 hours</time_frame>
    <description>Plasma maximum serum concentration of ceftaroline Area-under-the-concentration-time curve of ceftaroline: Time frame Predose (time zero [0]) to 12 hours Total body clearance of ceftaroline Apparent volume of distribution of ceftaroline Elimination rate constant of ceftaroline Elimination half-life of ceftaroline Renal clearance of ceftaroline: Time frame Predose (time zero [0]) to 12 hours Amount of ceftaroline excreted in the urine: Time frame Predose (time zero [0]) to 12 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety and tolerability of intravenous ceftaroline</measure>
    <time_frame>24 hours</time_frame>
    <description>Number of participants with adverse events Number of participants with changes in clinical laboratories Number of participants with changes in vital sign assessments</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Drug Safety</condition>
  <arm_group>
    <arm_group_label>Ceftaroline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ceftaroline intravenous 600 mg single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ceftaroline</intervention_name>
    <description>A single dose of ceftaroline fosamil 600 mg as a 1-hour continuous intravenous infusion</description>
    <arm_group_label>Ceftaroline</arm_group_label>
    <other_name>Teflaro</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy adult subjects

          -  nonsmokers within the last 1 year

          -  body mass index and total body weight within specific categories

        Exclusion Criteria:

          -  history of significant hypersensitivity reaction or intolerance to ceftaroline or
             beta-lactam agents or heparin

          -  aspartate or alanine aminotransferase &gt;3 times the upper limit of normal

          -  estimated creatinine clearance &lt;60 mL/minute and serum creatinine &gt;1.5 mg/dL

          -  female subjects who are pregnant or breast feeding

          -  history of alcohol or substance abuse or dependence within the last 1 year

          -  use of prescription or nonprescription drugs within last 7 to 14 days

          -  participations in a clinical trials within last 30 days

          -  donated blood (&gt;500 mL) within the last 56 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keith A Rodvold, Pharm.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Illinois at Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 16, 2012</study_first_submitted>
  <study_first_submitted_qc>July 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2012</study_first_posted>
  <last_update_submitted>March 12, 2013</last_update_submitted>
  <last_update_submitted_qc>March 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Illinois at Chicago</investigator_affiliation>
    <investigator_full_name>Keith A. Rodvold</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Ceftaroline</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Obesity</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cephalosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

